Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	43.32B
Revenue (ttm)	4.76B
Net Income (ttm)	1.98B
Shares Out	450.00M
EPS (ttm)	4.41
PE Ratio	21.82
Forward PE	22.49
Dividend	0.80 (0.83%)
Ex-Dividend Date	Sep 10, 2025

Volume	2,732,058
Average Volume	2,785,109
Open	97.50
Previous Close	96.27
Day's Range	97.12 - 99.16
52-Week Range	57.03 - 122.20
Beta	0.46
RSI	44.79
Earnings Date	Apr 23, 2026

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,417
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2024, SHA:688578's revenue was 3.56 billion, an increase of 76.29% compared to the previous year's 2.02 billion. Earnings were 1.43 billion, an increase of 121.97%.